Riociguat denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for riociguat are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Step Therapy to Riociguat

Step therapy (sometimes called "fail-first") requires that you try and document inadequate response to one or more lower-cost alternatives before BCBS will approve riociguat (Adempas). For pulmonary hypertension, this often means demonstrating that other approved agents in a different drug class were trialed first. Step-therapy denials are among the most frequently overturned on appeal because many patients have already tried alternative agents — the problem is usually that the prior-treatment history was not properly documented in the PA submission.

## Why This Denial Is Appealable

If you have already tried the required step(s), this denial can be overturned by providing complete documentation of that history. If your prescriber determined that the required prior therapy is contraindicated or clinically inappropriate for your specific case, most states and many plans recognize a "step-therapy exception" — your prescriber should submit a letter explaining the clinical reason the required step cannot be safely or appropriately attempted. Federal and many state laws strengthen patients' rights to step-therapy exceptions.

## Federal Appeal Framework

• Internal appeal: File within the timeframe stated on your denial notice. Under ERISA §503 and ACA §2719, BCBS must conduct a full-and-fair review and provide a written decision citing the specific criteria not met.
• External review: If the internal appeal is denied, you may request IRO external review. Federal rules generally provide approximately four months from the internal-appeal decision to file. The IRO will independently evaluate whether the step-therapy requirement is clinically appropriate given your medical history.
• Expedited appeal: Request expedited processing if the delay poses a serious health risk.

## Documentation to Gather

• Prior-treatment record: For each required step drug, provide the prescriber name, start date, end date, doses trialed, and the documented reason for discontinuation or inadequate response. Pharmacy dispensing records can corroborate dates.
• Prescriber exception letter: If a step drug is contraindicated or otherwise clinically inappropriate, the prescriber must explain why in writing, referencing your specific clinical findings.
• Current clinical status: Notes documenting disease severity, functional status, and the urgency of initiating riociguat.
• BCBS step-therapy criteria: Download the current published policy to confirm exactly which agents are required and in what order.

## Criteria-Mapping Structure

For each required step in BCBS's policy, create a row in a table: left column states the requirement exactly as written; right column provides the specific chart evidence, date, and outcome. Where a step was skipped due to clinical appropriateness, note the prescriber's documented rationale. A complete, organized submission removes the ability to deny on grounds of incomplete documentation.